RESCEU Project

RESCEU project aims to develop robust evidence on RSV disease burden & economic impact. It has received funding from IMI2 JU, GA N 116019 - H2020 R&I & EFPIA

[RESCEU Project @RESCEUproject]

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking JU and others. Any related tweets reflect only the views of the author.

[RESCEU Project @RESCEUproject]

Read the ���Vaccine’ #journal #article from @ElsevierConnect in full here: https://t.co/IIg2pXyovN
@Promise_IMI @IHIEurope

[RESCEU Project @RESCEUproject]

📣 New @RESCEU #paper

👉For the first time, costs and health-related quality of life (HRQoL) effects associated with RSV in healthy term infants and their caregivers in a community setting in four European countries have been evaluated.

@promise_IMI @IHIEurope @zhuxinmmm

[RESCEU Project @RESCEUproject]

Our research highlights the significant cost and HRQoL losses associated with RSV. These findings can help quantify the disease burden of RSV and inform future decision-making regarding interventions to protect young children from this disease.

[Charlotte Vernhes @CCVernhes]

.@BeutelsPhilippe of University of Antwerp closes the health economics session of #RSVVW23 by presenting insights from the @RESCEUproject @IHIEurope @ReSViNET

[Charlotte Vernhes @CCVernhes]

Brenda is part of the @RESCEUproject and @PROMISE_IMI Patient Advisory Board and is involved in #RSV research and awareness raising 👏

[RESCEU Project @RESCEUproject]

6/6
📖 Read the ‘Vaccine’ #journal #article from @ElsevierConnect in full here:
https://t.co/QE1bcX0G5q
@Promise_IMI @IHIEurope

[RESCEU Project @RESCEUproject]

📣 New @RESCEU #paper on #RSV monoclonal antibody and maternal immunization in 6 European countries suggests seasonal programme with or without catch-up could be cost-effective or even cost-saving.

@Promise_IMI @IHIEurope

👇Follow the 🧵 #Thread for key results:
1/6

[RESCEU Project @RESCEUproject]

The choice between a maternal immunization or monoclonal antibodies depends on the level and duration of protection, price, availability and age-specific RSV-attributable hospitalizations in very young children, which should be based on the latest available evidence.

[John Paget, PhD @PagetPhd]

Another @RESCEUproject publication 💪

Congratulations to all involved, including @JJGTvanSummeren

https://t.co/rIOpWFVlMR

[RESCEU Project @RESCEUproject]

5/5
📖 Read the ‘Value in Health’ #journal #article from @ElsevierConnect in full here:
https://t.co/6juTK8Low8

@PROMISE_IMI @IHIEurope

[RESCEU Project @RESCEUproject]

1/5
📣 #NewPaper by @RESCEUproject #scientists!

📖Read the latest publication in @ElsevierConnect on the cost-effectiveness of #RSV (Respiratory Syncytial Virus) interventions in children.

@PROMISE_IMI @IHIEurope @WHO_Europe_VPI

👇Follow the🧵#Thread for key results:

[RESCEU Project @RESCEUproject]

4/5
But we found important differences on non-medically attended symptomatic RSV burden and waning immunity. These aspects need more attention in future trials and analyses.
👇

[Innovative Health Initiative @IHIEurope]

#RSV is in the headlines, with cases rising across Europe. IMI project @RESCEUproject shed new light on the burden of RSV, knowledge that could improve how the disease is managed, treated (and hopefully prevented) in the future.
https://t.co/dsRMawKEHa
#RespiratorySyncitialVirus